NeuroMetrix Inc
Change company Symbol lookup
Select an option...
NURO NeuroMetrix Inc
OTTW Ottawa Savings Bancorp Inc
HMC Honda Motor Co Ltd
PAVMZ PAVmed Series Z Equity Warrants Exp 30 Apr 2024 *W EXP 04/30/2024
FFBW Ffbw Inc
CIB Bancolombia SA
TARA Protara Therapeutics Inc
SLAMU Slam Corp
SY So-Young International Inc
BHR Braemar Hotels & Resorts Inc
Go

Health Care : Health Care Equipment & Supplies | Small Cap Value
Company profile

NeuroMetrix, Inc. develops and commercializes health care products that utilize non-invasive neurostimulation. The Company is engaged in the designing, building and marketing of medical devices that stimulate nerves and analyze nerve response for diagnostic and therapeutic purposes. It has two principal product categories, which includes point-of-care neuropathy diagnostic tests and wearable neurostimulation devices. Its products include DPNCheck, Quell and ADVANCE System. DPNCheck is a quantitative nerve conduction test that is used to evaluate peripheral neuropathies, such as Diabetic peripheral neuropathy (DPN). Quell a wearable device for symptomatic relief and management of chronic pain. ADVANCE System is a platform for the performance of nerve conduction studies. DPNCheck customers include managed care organizations, endocrinologists, podiatrists and primary care physicians. ADVANCE System customers include occupational health, primary care, internal medicine and many others.

Closing Price
$3.64
Day's Change
-0.04 (-1.09%)
Bid
--
Ask
--
B/A Size
--
Day's High
3.67
Day's Low
3.45
Volume
(Light)
Volume:
23,881

10-day average volume:
71,663
23,881

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors International Business Machines Corporation - IBM

6:05 pm ET May 17, 2022 (Globe Newswire) Print

EQNX::TICKER_START (NYSE:IBM), EQNX::TICKER_END Pomerantz LLP is investigating claims on behalf of investors of International Business Machines Corporation ("IBM" or the "Company") (NYSE: IBM). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether IBM and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On October 16, 2018, IBM issued a press release announcing its preliminary results for its third quarter of 2018. The Company reported revenue of $18.8 billion, down 2%, and slowing growth in its "Strategic Imperatives" line of business.

On this news, IBM's stock price fell $11.07 per share, or 7.6%, to close at $134.05 per share on October 17, 2018.

Then, on October 20, 2021, IBM issued a press release announcing its results for its third quarter of 2021. The Company announced total revenues for the quarter of $17.62 billion, a shortfall of $191.84 million based on analyst estimates. The main culprit was the Cloud & Cognitive Software segment, which had revenues of $5.69 billion, a shortfall of approximately $80 million based on analyst estimates of $5.77 billion. Over 42% of the shortfall of approximately $190 million was attributable to Cloud & Cognitive Software (including IBM's Watson business), the segment where most of the strategic revenue produced by the Company's reclassification of revenues from non-strategic to strategic historically went.

On this news, IBM's stock price fell $12.80 per share, or 9.56%, to close at $121.07 per share on October 21, 2021.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:

Robert S. Willoughby

Pomerantz LLP

rswilloughby@pomlaw.com

888-476-6529 ext. 7980

https://ml.globenewswire.com/media/MGU2NzI4MDItMWQwMi00NjE3LTgxZTUtZmJiZTgzZTRiMmM3LTEwMjkyMTc=/tiny/Pomerantz-LLP.png

https://ml.globenewswire.com/media/MGU2NzI4MDItMWQwMi00NjE3LTgxZTUtZmJiZTgzZTRiMmM3LTEwMjkyMTc=/tiny/Pomerantz-LLP.png

comtex tracking

COMTEX_407351335/2010/2022-05-17T18:05:39

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.